Table 4.
Investigational drugs for the treatment of cancer cachexia.
| ClinicalTrials. gov identifier | Title | Phase | Mechanism of action | Sponsor | References |
|---|---|---|---|---|---|
| NCT01206335 | Open label study with OHR/AVR118 in advanced cancer patients with anorexia-cachexia | II | Broad spectrum peptide-nucleic acid immunomodulator targeting cytokine production (including TNF-α and IL-6) | Ohr Pharmaceutical Inc. | ClinicalTrials.gov. Open label study with OHR/AVR118 in advanced cancer patients with anorexia-cachexia |
| NCT01433263 | Clinical study BYM338 for the treatment of unintentional weight loss in patients with cancer of the lungs or the pancreas | II | Human monoclonal antibody against activin receptor type 2B (ACVR2B) | Novartis Pharmaceuticals | ClinicalTrials.gov. Clinical study of BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas |
| NCT01505530 | A phase 2 study of LY2495655 in participants with pancreatic cancer | II | Humanized monoclonal antibody against myostatin | Eli Lilly and Company | ClinicalTrials.gov. A Phase 2 study of LY2495655 in participants with pancreatic cancer |